Advertisement

Approach to the Patient with Nausea and Vomiting in Pregnancy

  • Lindsey DeGeorge
  • Lauren WiesnerEmail author
Chapter

Abstract

A stepwise approach can be utilized for the assessment and treatment of nausea and vomiting in pregnancy and its most severe form, hyperemesis gravidarum. Prompt treatment is important to prevent further progression of symptoms. Diagnostic testing should focus on evaluation for signs of dehydration and electrolyte disturbance. In addition to volume and vitamin repletion, the use of antiemetic medications pyridoxine with doxylamine as first-line therapy is recommended for mild symptoms. Management of persistent/severe symptoms may include use of diphenhydramine, metoclopramide, ondansetron, and promethazine as second-line agents. Hospital admission is reserved for cases of refractory vomiting requiring continued intravenous antiemetics, failed outpatient management of symptoms, and severe fluid or electrolyte imbalance.

Keywords

Hyperemesis gravidarum Nausea Vomiting Dehydration Antiemetic 

References

  1. 1.
    Einarson TR, Piwko C, Koren G. Prevalence of nausea and vomiting of pregnancy in the USA: a meta analysis. J Popul Ther Clin Pharmacol. 2013;20(2):e163–70.PubMedGoogle Scholar
  2. 2.
    Piwko C, Koren G, Babashov V, Vicente C, Einarson TR. Economic Burden of nausea and vomiting of pregnancy in the USA. J Popul Ther Clin Pharmacol. 2013;20(2):e149–60. Epub 2013 Jul 10PubMedGoogle Scholar
  3. 3.
    Sheehan P. Hyperemesis gravidarum – assessment and management. Aust Fam Physician. 2007;36(9):698–701.PubMedGoogle Scholar
  4. 4.
    Boelig RC, Barton SJ, Saccone G, Kelly AJ, Edwards SJ, Berghella V. Interventions for treating hyperemesis gravidarum. Cochrane Database Syst Rev. 2016;(5). Art. No.: CD010607.Google Scholar
  5. 5.
    Eliakim R, Abulafiaz O, Shere DM. Hyperemesis gravidarum: a current review. Am J Perinatol. 2000;17(4):207–18.Google Scholar
  6. 6.
    Body C, Christie J. Gastrointestinal disease in pregnancy. Gastroenterol Clin North Am. 2016;45:267–83.CrossRefPubMedGoogle Scholar
  7. 7.
    World Health Organization. International classification of diseases: 10. Version: 2010. 2012. http://tinyurl.com/ctcuekp. Accessed 29 June 2016.
  8. 8.
    Summers A. Emergency management of hyperemesis gravidarum. Emerg Nurse. 2012;20(4):24–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Kuscu NK, Koyuncu F. Hyperemesis gravidarum: current concepts and management. Postgrad Med J. 2002;78(916):76–9.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Zhang Y, Cantor RM, MacGibbon K, Romero R, Goodwin TM, Mullin PM, Feizo MS. Familial aggregation of hyperemesis gravidarum. Am J Obstet Gynecol. 2011;204(3):230.e1–7.CrossRefGoogle Scholar
  11. 11.
    Schiff MA, Reed SD, Daling JR. The sex ratio of pregnancies complicated by hospitalisation for hyperemesis gravidarum. BJOG. 2004;111:27–30.CrossRefPubMedGoogle Scholar
  12. 12.
    Tan JYL, Loh KC, Yeo GSH, Chee YC. Transient hyperthyroidism of hyperemesis gravidarum. BJOG. 2002;109:683–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Ismail SK, Kenny L. Review on hyperemesis gravidarum. Clin Gastroenterol. 2007;21(5):755–69.Google Scholar
  14. 14.
    Vutyavanich T, Kraisarin T, Ruangsri R. Ginger for nausea and vomiting in pregnancy: randomised, double masked, placebo controlled trial. Obstet Gynecol. 2001;97:577–82.PubMedGoogle Scholar
  15. 15.
    Fischer-Rasmussen W, Kiaer SK, Dahl C, Asping U. Ginger treatment of hyperemesis gravidarum. Eur J Obstet Gynecol Reprod Biol. 1991;38(1):19–24.CrossRefPubMedGoogle Scholar
  16. 16.
    Borrelli F, Capasso R, Aviello G, et al. Effectiveness and safety of ginger in the treatment of pregnancy-induced nausea and vomiting. Obstet Gynecol. 2005;105(4):849–56.CrossRefPubMedGoogle Scholar
  17. 17.
    American College of Obstetricians and Gynecologists Practice Bulletin. Number 153. 2015. http://dx.doi.org/10.1097/AOG.0000000000001048. Accessed 29 June 2016.
  18. 18.
    Grooten IJ, et al. A systematic review and meta-analysis of the utility of corticosteroids in the treatment of hyperemesis gravidarum. Nutr Metab Insights. 2015;8(S1):23–32.PubMedGoogle Scholar
  19. 19.
    Duchesnay Inc. Bendectin history. 2013. http://www.bendectin.com/en. Accessed 29 June 2016
  20. 20.
    American College of Obstetrics and Gynecology. Practice Bulletin No 153.Google Scholar
  21. 21.
    Kutcher JS, Engle A, Firth J, Lamm SH. Bendectin and birth defects. II: ecological analyses. Birth Defects Res A Clin Mol Teratol. 2003;67(2):88–97.CrossRefPubMedGoogle Scholar
  22. 22.
    McKeigue PM, Lamm SH, Linn S, Kutcher JS. Bendectin and birth defects: I. A meta-analysis of the epidemiologic studies. Teratology. 1994;50(1):27–37.CrossRefPubMedGoogle Scholar
  23. 23.
    Goodwin T. Murphy hyperemesis gravidarum. Obstet Gynecol Clin. 2008;35(3):401–17.CrossRefGoogle Scholar
  24. 24.
    Pope E, Maltepe C, Koren G. Comparing pyridoxine and doxylamine succinate-pyridoxine HCl for nausea and vomiting of pregnancy: a matched, controlled cohort study. J Clin Pharmacol. 2015;55(7):809–14.CrossRefPubMedGoogle Scholar
  25. 25.
    Madjunkova S, Maltepe C, Koren G. The delayed-release combination of doxylamine and pyridoxine (Diclegis/Diclectin) for the treatment of nausea and vomiting of pregnancy. Paediatr Drugs. 2014;16(3):199–211.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Tobin S. Management of nausea and vomiting of pregnancy after discharge from the Emergency Department. Emerg Med News Duchesnay Suppl. 2016.Google Scholar
  27. 27.
    Matok I, Gorodischer R, Koren G, Sheiner E, Wiznitzer A, Levy A. The safety of metoclopramide use in the first trimester of pregnancy. N Engl J Med. 2009;360(24):2528–35.CrossRefPubMedGoogle Scholar
  28. 28.
    Magee LA, Mazzotta P, Koren G. Evidence-based view of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy (NVP). Am J Obstet Gynecol. 2002;186(5 Suppl Understanding):S256–61. 37CrossRefPubMedGoogle Scholar
  29. 29.
    Mayhall EA, Gray R, Lopes V, Matteson KA. Comparison of antiemetics for nausea and vomiting of pregnancy in an emergency department setting. Am J Emerg Med. 2015;33:882–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Oliveira LG, Capp SM, You WB, Riffenburgh RH, Carstairs SD. Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy. Obstet Gynecol. 2014;124:735–42.CrossRefPubMedGoogle Scholar
  31. 31.
    Abas MN, Tan PC, Azmi N, Omar SZ. Ondansetron compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial. Obstet Gynecol. 2014;123:1272–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Pasternak B, Svanström H, Hvild A. Ondansetron in pregnancy and risk of adverse fetal outcomes. N Engl J Med. 2013;368:814–23. Erratum in N Engl J Med 2013;368:2146CrossRefPubMedGoogle Scholar
  33. 33.
    Danielsson B, Wikner BN, Källén B. Use of ondansetron during pregnancy and congenital malformations in the infant. Reprod Toxicol. 2014;50:134–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Siminerio L, Bodnar L, Venkataramanan R, Caritis S. Ondansetron use in pregnancy. Obstet Gynecol. 2016;127:873–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Carstairs S. Ondansetron use in pregnancy and birth defects. Obstet Gynecol. 2016;127:878–83.CrossRefPubMedGoogle Scholar
  36. 36.
    Freedman SB, Uleryk E, Rumantir M, et al. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. Ann Emerg Med. 2014;64(1):19–25. e16CrossRefPubMedGoogle Scholar
  37. 37.
    Carmichael SL, Shaw GM, Ma C, et al. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol. 2007;197(6):585. e581–7. Discussion 683–684, e581–587.Google Scholar
  38. 38.
    Skuladottir H, Wilcox AJ, Ma C, et al. Corticosteroid use and risk of orofacial clefts. Birth Defects Res A Clin Mol Teratol. 2014;100(6):499–506.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Painter RC, Roseboom TJ, de Rooij SR. Long-term effects of prenatal stress and glucocorticoid exposure. Birth Defects Res C Embryo Today. 2012;96(4):315–24.CrossRefPubMedGoogle Scholar
  40. 40.
    Togay-Isikay C, Yigit A, Mutluer N. Wernicke’s encephalopathy due to hyperemesis gravidarum: an under-recognised condition. Aust N Z J Obstet Gynaecol. 2001;41:453–6.CrossRefPubMedGoogle Scholar
  41. 41.
    Chiossi G, Neri I, Cavazzuti M, Basso G, Facchinetti F. Hyperemesis gravidarum complicated by Wernicke encephalopathy: background, case report, and review of the literature. Obstet Gynecol Surv. 2006;61(4):255–68.CrossRefPubMedGoogle Scholar
  42. 42.
    Food and Drug Administration. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. 2014. https://federalregister.gov/a/2014-28241.

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of Emergency MedicineMedStar Washington Hospital CenterWashington, DCUSA

Personalised recommendations